Successful triple therapy of patients with chronic hepatitis C genotype 1 infection leads to significant improvement of non-invasive liver fibrosis tests

Background and Aim: The new standard of care for patients with chronic hepatitis C genotype 1 (GT1) is triple therapy with pegylated interferon alpha (P), ribavirin (R) and a HCV protease inhibitor (PI). Sustained virological response (SVR) has been shown to lower the incidence of HCC, improve survival and even regression of liver cirrhosis is suggested in some cases. However, data are limited, especially for triple therapy. We aim to evaluate the impact of SVR after triple therapy including PIs on liver fibrosis by non-invasive fibrosis measures in a real-world setting. Methods: Eighty-six patients with GT1 wer…